Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...
Hosted on MSN1d
Wegovy and Ozempic stars dim amid overuse concernsThe luster is starting to wear off GLP-1 weight-loss drugs including Wegovy and Ozempic as more clinicians warn patients ...
Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...
Hims & Hers hit the bulls-eye with its Super Bowl ad—it sparked a lot of attention from consumers to check out its brand and ...
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...
Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...
A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Recent studies reveal a concerning trend of vision loss among patients using Ozempic and other weight loss products, raising ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback